Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female infant between, and including, 60 and 90 days of age at the time of the first vaccination.~* Born after a gestation period of 36 to 42 weeks inclusive.~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative (LAR) (s) can and will comply with the requirements of the protocol.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP, Hib and/or hepatitis B vaccine(s).~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Evidence of previous or intercurrent poliomyelitis disease or vaccination.~* History of seizures or progressive neurological disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness.~* Child in care.~The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved and if no other exclusion criteria are met:~• Current febrile illness or axillary temperature \> 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- Poliorix Group (Type: EXPERIMENTAL): Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
- Control Group (Type: ACTIVE_COMPARATOR): Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.

Based on this trial design, predict the completion outcome and termination type (if applicable).